SynthesisFrontiers in pharmacology2025
Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role and mechanism of quercetin via the TLR4/MyD88/IRAK4 signaling pathway in the treatment of allergic rhinitis.Experimental and therapeutic medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Quercetin is a naturally occurring flavonoid widely present in fruits, vegetables and tea with multiple pharmacological activities, including immunomodulatory, anti-allergic, antioxidant and anti-inflammatory properties. Preclinical studies have indicated the potential to ameliorate allergic symptoms in animal models, but comprehensive synthesis is still scarce. Objective: This meta-analysis was conducted to summarize the therapeutic effects of quercetin in allergic disease models and explore its potential mechanisms. Methods: According to PRISMA recommendations, preclinical studies were extracted from PubMed, Web of Science and Embase databases. Thirteen eligible studies were extracted for quantitative synthesis analysis. In total, 13 studies using murine models (BALB/c, C57BL/6 mice, SKH-1 hairless mice and NC/Nga mice; Wistar and Sprague-Dawley rats) were included. The most closely related biomarkers were total IgE, OVA-specific IgE, histamine, inflammatory cytokines (IL-4, IL-5, IL-10, TNF-α, IFN-γ), and immune cell populations (macrophages, lymphocytes, eosinophils, neutrophils). Review Manager 5.4 software was used for analysis, and standardized mean differences (SMD) and 95% confidence intervals (CI) were calculated under a random-effects model. Results: The meta-analysis showed that quercetin significantly decreased the expression of total IgE, OVA-specific IgE, and histamine, and suppressed the infiltration of eosinophils, macrophages, and lymphocytes. Cytokine profiling showed that quercetin significantly suppressed the expression of IL-4 and TNF-α, and increased the expression of IFN-γ, which may contribute to the underlying anti-inflammatory mechanism of quercetin through Th1/Th2 immune rebalancing. Conclusion: Quercetin exhibits strong anti-allergic effects in preclinical models through suppression of IgE, modulation of immune cells, regulation of cytokine network, and reduction of histamine. However, large inter-study heterogeneity and methodological limitations in original studies should be cautiously interpreted. Application in clinical settings should be carefully evaluated through well-designed trials to validate safety, efficacy, and molecular mechanisms in human populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.